RE:RE:Covid implications for meetings with shareholdersSo much to unpack here but at least I am amusing you - there is value in that!
I said apparently because we don't really know if it is actually still ongoing. But I did hear from someone recently who indicated they had contacted the Gettysburg Hospital and were told the trial was ongoing but that it was hard to get into because they were only accepting one patient at a time. Of course, I don't know if that info was fully accurate as the hospital employee this person likely spoke to was probably a junior assistant type who likely had dated info. This info came in within the last week or so which indicates they are not yet at the data analysis stage. But, again, it may not be fully accurate.
My sense from others I have spoken to, who had contact with TH, was that the trial was still ongoing in late December.
But it may be no longer enrolling new patients. We simply cannot know for sure until the comopany says so. And since they have not said the MTD has been reached, then it seems safe to assume the trial is ongoing at this time. That could change tomorrow.
Also, I suspect they could tell us the MTD as soon as it has been reached and before all the trial data has been analyzed based on the wording of their previous statement. So, since they have not told us it has been reached, the trial is apparently ongoing.
The announcement I am expecting prior to the meetings with the large shareholders in late January feels more like a corporate event than trial results. Again, I want to emphasize I am totally specualting on this based on the hints already highlighted and could be totally off the mark. It just feels like something has already been agreed to in a corporate sense and they are awaiting on formal board approval before announcing it. Now, I agree that it seems too early for any such corporate events to be occurring in cancer so maybe there is something going to be announced on NASH.
Clearly, the most important piece of info we would like to hear based on what we know right now is whether there has been any evidence of tumor regression seen in the sortilin overexpressing tumors in the phase 1a. If we have to wait until phase 1b to see that, it would be disappointing as the risk profile of TH-1902 will not have been reduced much as a result of the phase 1a trial results. And it will bring up a lot of hard questions about potential financings as JFM1330 pointed out earleir today.
longterm56 wrote: I'm frequently amused by your wording, SPCEO. "
the fact that the trial is
apparantly still ongoing." ... so that is an "apparent fact"? Not sure what that means.
It is not only possible, but very likely, that this big January event is to announce the results of Phase 1a, which means it was probably concluded a couple months ago and they have been summarizing their findings and preparing for the big release (including a new investors presentation). It doesn't seem reasonable to meet with big shareholders if Phase 1a is still on a sliding schedule to which we are not being informed. Wouldn't that be the first question that big shareholders would ask?
-LT
SPCEO1 wrote:
<snip>
The biggest hint we have on the most important subject for TH right now is the fact that the trial is apparently still ongoing. So, very large doses of TH-1902 are still being given to patients and the odds that those patients with sortilin overexpressing cancers are seeing some positive impact on their tumors grows each day.
We will know soon enough.